Blood protein predictors of brain amyloid for enrichment in clinical trials?

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 1, Issue 1, 2015, Pages 48-60

  Ashton, Nicholas J ^a,b   Kiddle, Steven J ^a,c   Graf, John ^d   Ward, Malcolm ^a   Baird, Alison L ^a,e   Hye, Abdul ^a,b   Westwood, Sarah ^a,b   Wong, Karyuan Vivian ^a   Dobson, Richard J ^a,b   Rabinovici, Gil D ^f   Miller, Bruce L ^f   Rosen, Howard J ^f   Torres, Andrew ^d   Zhang, Zhanpan ^d   Thurfjell, Lennart ^g   Covin, Antonia ^h   Hehir, Cristina Tan ^d   Baker, David ^h   Bazenet, Chantal ^a,b   Lovestone, Simon ^a,e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d GE GLOBAL RESEARCH   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g GE Healthcare Life Sciences   (Sweden)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Alzheimer's disease; Biomarker; Clinical trials; Fibrinogen chain; Plasma; Proteomics; amyloid

Indexed keywords

EID: 84937044904     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2014.11.005     Document Type: Article

References (52)

1. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6:131-144.
2. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
3. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013, 12:357-367.
4. Corbett A., Smith J., Ballard C. New and emerging treatments for Alzheimer's disease. Expert Rev Neurother 2012, 12:535-543.
5. Aisen P.S., Vellas B., Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov 2013, 12:324.
6. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
7. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., et al. Post-mortem correlates of invivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
8. Nelissen N., Van Laere K., Thurfjell L., Owenius R., Vandenbulcke M., Koole M., et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009, 50:1251-1259.
9. Johnson K.A., Sperling R.A., Gidicsin C.M., Carmasin J.S., Maye J.E., Coleman R.E., et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013, 9(5 Suppl):S72-S83.
10. Nordberg A., Rinne J.O., Kadir A., Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol 2010, 6:78-87.
11. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004, 55:306-319.
12. Ng S., Villemagne V.L., Berlangieri S., Lee S.T., Cherk M., Gong S.J., et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 2007, 48:547-552.
13. Rabinovici G.D., Rosen H.J., Alkalay A., Kornak J., Furst A.J., Agarwal N., et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011, 77:2034-2042.
14. Jagust W.J., Landau S.M., Shaw L.M., Trojanowski J.Q., Koeppe R.A., Reiman E.M., et al. Relationships between biomarkers in aging and dementia. Neurology 2009, 73:1193-1199.
15. Scheinin N.M., Aalto S., Koikkalainen J., Lotjonen J., Karrasch M., Kemppainen N., et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009, 73:1186-1192.
16. Villain N., Chetelat G., Grassiot B., Bourgeat P., Jones G., Ellis K.A., et al. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: A voxelwise PiB-PET longitudinal study. Brain 2012, 135:2126-2139.
17. Blennow K., Hampel H., Zetterberg H. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology 2014, 39:189-201.
18. Salloway S., Sperling R., Fox N.C., Blennow K., Klunk W., Raskind M., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:322-333.
19. Koyama A., Okereke O.I., Yang T., Blacker D., Selkoe D.J., Grodstein F. Plasma amyloid-β as a predictor of dementia and cognitive decline: A systematic review and meta-analysis. Arch Neurol 2012, 69:824-831.
20. Kiddle S.J., Sattlecker M., Proitsi P., Simmons A., Westman E., Bazenet C., et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: A systematic review and replication study. J Alzheimers Dis 2014, 38:515-531.
21. Lista S., Faltraco F., Prvulovic D., Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol 2013, 101-102:1-17.
22. Zurbig P., Jahn H. Use of proteomic methods in the analysis of human body fluids in Alzheimer research. Electrophoresis 2012, 33:3617-3630.
23. Guntert A., Campbell J., Saleem M., O'Brien D.P., Thompson A.J., Beyers H.L., et al. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis 2010, 21:585-596.
24. Sattlecker M., Kiddle S.J., Newhouse S., Proitsi P., Nelson S., Williams S., et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement 2014, 10:724-734.
25. Song F., Poljak A., Crawford J., Kochan N.A., Wen W., Cameron B., et al. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One 2012, 7:e34078.
26. Thambisetty M., Simmons A., Hye A., Campbell J., Westman E., Zhang Y., et al. Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One 2011, 6:e28527.
27. Hye A., Riddoch-Contreras J., Baird A.L., Ashton N.J., Bazenet C., Leung R., et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 2014, 10:799-807.
28. Thambisetty M., Hye A., Foy C., Daly E., Glover A., Cooper A., et al. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol 2008, 255:1712-1720.
29. Thambisetty M., Tripaldi R., Riddoch-Contreras J., Hye A., An Y., Campbell J., et al. Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis 2010, 22:1099-1109.
30. Kiddle S.J., Thambisetty M., Simmons A., Riddoch-Contreras J., Hye A., Westman R., et al. Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS One 2012, 7:e44260.
31. Burnham S.C., Faux N.G., Wilson W., Laws S.M., Ames D., Bedo J., et al. A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: Results from the AIBL study. Mol Psychiatry 2014, 19:519-526.
32. Ellis K.A., Bush A.I., Darby D., De Fazio D., Foster J., Hudson P., et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009, 21:672-687.
33. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010, 31:1275-1283.
34. Dayon L., Hainard A., Licker V., Turck N., Kuhn K., Hochstrasser D.F., et al. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 2008, 80:2921-2931.
35. Carrillo B., Yanofsky C., Laboissiere S., Nadon R., Kearney R.E. Methods for combining peptide intensities to estimate relative protein abundance. Bioinformatics 2010, 26:98-103.
36. Bettcher B.M., Watson C.L., Walsh C.M., Lobach I.V., Neuhaus J., Miller J.W., et al. Interleukin-6, age, and corpus callosum integrity. PLoS One 2014, 9:e106521.
37. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
38. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E., et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
39. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998, 51:1546-1554.
40. Lehmann M., Ghosh P.M., Madison C., Laforce R., Corbetta-Rastelli C., Weiner M.W., et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013, 136:844-858.
41. Blacker D., Haines J.L., Rodes L., Terwedow H., Go R.C., Harrell L.E., et al. ApoE-4 and age at onset of Alzheimer's disease: The NIMH genetics initiative. Neurology 1997, 48:139-147.
42. Thambisetty M., An Y., Nalls M., Sojkova J., Swaminathan S., Zhou Y., et al. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry 2013, 73:422-428.
43. van Oijen M., Witteman J.C., Hofman A., Koudstaal P.J., Breteler M.M. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 2005, 36:2637-2641.
44. Xu G., Zhang H., Zhang S., Fan X., Liu X. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int J Clin Pract 2008, 62:1070-1075.
45. Cortes-Canteli M., Paul J., Norris E.H., Bronstein R., Ahn H.J., Zamolodchikov D., et al. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: A possible contributing factor to Alzheimer's disease. Neuron 2010, 66:695-709.
46. Ryu J.K., McLarnon J.G. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J Cell Mol Med 2009, 13:2911-2925.
47. Paul J., Strickland S., Melchor J.P. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 2007, 204:1999-2008.
48. Marques F., Sousa J.C., Sousa N., Palha J.A. Blood-brain-barriers in aging and in Alzheimer's disease. Mol Neurodegener 2013, 8:38.
49. Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., Pendu R., et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007, 13:1029-1031.
50. Klohs J., Baltes C., Princz-Kranz F., Ratering D., Nitsch R.M., Kneusel I., et al. Contrast-enhanced magnetic resonance microangiography reveals remodeling of the cerebral microvasculature in transgenic ArcAβ mice. J Neurosci 2012, 32:1705-1713.
51. Ahn H.J., Zamolodchikov D., Cortes-Canteli M., Norris E.H., Glickman J.F., Strickland S. Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A 2010, 107:21812-21817.
52. Jedynak B.M., Lang A., Liu B., Katz E., Zhang Y., Wyman B.T., et al. A computational neurodegenerative disease progression score: Method and results with the Alzheimer's Disease Neuroimaging Initiative cohort. Neuroimage 2012, 63:1478-1486.